started · updated
Roche suspends future investment decisions in Germany
Swiss pharmaceutical giant Roche has announced a temporary suspension of all future investment decisions in Germany. Daniel Steiners, head of Roche Germany, stated that recent political decisions have “destroyed a great deal of trust” within the pharmaceutical sector.
The decision stems from the GKV Contribution Rate Stabilization Act, a legislative reform passed in July aimed at containing rising statutory health insurance expenditures. Under this law, pharmaceutical companies must increase the mandatory rebate on most branded medicines from 7% to 15.5% starting next year. While the German government argues these measures are necessary to prevent increases in social security contributions, industry leaders contend the policy imposes undue financial burdens and undermines the country's attractiveness as a high-value industrial location.
This announcement coincides with a government-led investment summit in Berlin intended to attract international capital. Roche's move follows similar warnings from other major firms, including Eli Lilly, which halved its planned investment in Rhineland-Palatinate, and Boehringer Ingelheim, which canceled 900 million euros in planned expenditures. Roche currently employs approximately 18,600 people in Germany.
Entities
Daniel Steiners · Eli Lilly · Friedrich Merz · Germany · Katherina Reiche · Merz Government · Roche
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 9 SOURCES] Roche employs approximately 18,600 people in Germany. www.kurierverlag.de · www.merkur.de · www.mannheim24.de · www.aerzteblatt.de · www.cash.ch · +4 more
- [● 22 SOURCES] Roche has suspended all future investment decisions in Germany. www.kurierverlag.de · www.merkur.de · www.focus.de · www.mannheim24.de · www.onetz.de · +17 more
- [● 14 SOURCES] The GKV reform intends to increase the financial burden on pharmaceutical companies. www.kurierverlag.de · www.focus.de · www.mannheim24.de · www.merkur.de · www.onetz.de · +9 more
- [● 22 SOURCES] The German government's health policy has destroyed trust in the pharmaceutical industry. www.kurierverlag.de · www.merkur.de · www.focus.de · www.mannheim24.de · www.onetz.de · +17 more
- [● 14 SOURCES] The GKV reform aims to limit rising statutory health insurance expenditures and prevent contribution increases. www.kurierverlag.de · www.merkur.de · www.mannheim24.de · www.onetz.de · www.aerzteblatt.de · +9 more
- [● 12 SOURCES] The GKV Contribution Rate Stabilization Act is a central cause of the conflict. www.kurierverlag.de · www.focus.de · www.mannheim24.de · www.merkur.de · www.onetz.de · +7 more
- [● 3 SOURCES] Eli Lilly halved its planned 2.5 billion euro investment in Rhineland-Palatinate. www.aerzteblatt.de · telegrafi.com · www.tagesschau.de
- [● 2 SOURCES] Boehringer Ingelheim canceled planned expenditures of 900 million euros. www.aerzteblatt.de · formiche.net
- [● 8 SOURCES] Starting in 2027, pharmaceutical manufacturers must provide a 15.5 percent discount on most brand-name drugs. de.euronews.com · es.euronews.com · dailydigest.ie · www.cnbce.com · www.kurierverlag.de · +3 more